Hennion & Walsh Asset Management Inc. Reduces Stake in Humana Inc. (NYSE:HUM)

Hennion & Walsh Asset Management Inc. lessened its stake in shares of Humana Inc. (NYSE:HUM) by 26.1% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,774 shares of the insurance provider’s stock after selling 625 shares during the quarter. Hennion & Walsh Asset Management Inc.’s holdings in Humana were worth $562,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Pzena Investment Management LLC grew its stake in Humana by 538.7% during the second quarter. Pzena Investment Management LLC now owns 2,318,347 shares of the insurance provider’s stock valued at $866,250,000 after acquiring an additional 1,955,375 shares in the last quarter. Davis Selected Advisers grew its position in shares of Humana by 16.1% during the 2nd quarter. Davis Selected Advisers now owns 2,311,362 shares of the insurance provider’s stock valued at $863,640,000 after purchasing an additional 321,233 shares in the last quarter. Marshall Wace LLP increased its holdings in shares of Humana by 118.9% in the second quarter. Marshall Wace LLP now owns 1,425,302 shares of the insurance provider’s stock worth $532,564,000 after purchasing an additional 774,085 shares during the period. Legal & General Group Plc raised its position in shares of Humana by 2.1% in the second quarter. Legal & General Group Plc now owns 1,183,985 shares of the insurance provider’s stock worth $442,396,000 after buying an additional 24,842 shares in the last quarter. Finally, Ontario Teachers Pension Plan Board boosted its stake in Humana by 11,647.2% during the first quarter. Ontario Teachers Pension Plan Board now owns 1,059,478 shares of the insurance provider’s stock valued at $367,342,000 after buying an additional 1,050,459 shares during the period. 92.38% of the stock is currently owned by institutional investors.

Humana Stock Up 0.1 %

Shares of NYSE HUM opened at $261.09 on Tuesday. The firm’s fifty day moving average is $304.67 and its 200 day moving average is $335.98. Humana Inc. has a 52 week low of $213.31 and a 52 week high of $527.18. The company has a quick ratio of 1.66, a current ratio of 1.66 and a debt-to-equity ratio of 0.70. The company has a market cap of $31.46 billion, a price-to-earnings ratio of 16.26, a PEG ratio of 2.04 and a beta of 0.50.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.89 by $1.07. The firm had revenue of $29.54 billion for the quarter, compared to analysts’ expectations of $28.52 billion. Humana had a net margin of 1.53% and a return on equity of 16.12%. The company’s revenue for the quarter was up 10.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $8.94 earnings per share. On average, equities research analysts expect that Humana Inc. will post 16.06 earnings per share for the current year.

Humana Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be issued a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 1.36%. The ex-dividend date of this dividend is Tuesday, December 31st. Humana’s dividend payout ratio (DPR) is currently 22.04%.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Barclays lowered their price target on Humana from $364.00 to $250.00 and set an “equal weight” rating on the stock in a report on Thursday, October 10th. Bank of America downgraded shares of Humana from a “neutral” rating to an “underperform” rating and lowered their target price for the company from $376.00 to $247.00 in a research note on Wednesday, October 2nd. KeyCorp initiated coverage on shares of Humana in a research note on Friday, October 11th. They issued a “sector weight” rating for the company. TD Cowen cut shares of Humana from a “buy” rating to a “hold” rating and lowered their price objective for the company from $402.00 to $261.00 in a research report on Monday, October 7th. Finally, Piper Sandler lowered shares of Humana from an “overweight” rating to a “neutral” rating and cut their target price for the stock from $392.00 to $274.00 in a research report on Thursday, October 3rd. One research analyst has rated the stock with a sell rating, nineteen have issued a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $315.33.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.